ライフサイエンスコーパス: cryosurgery

1 gate the MTD for patients who have undergone cryosurgery.

2 ization, percutaneous ethanol injection, and cryosurgery.

3 69 years) with prostate cancer who underwent cryosurgery.

4 % in patients examined 8 weeks or more after cryosurgery.

5 lone or in combination with open superficial cryosurgery.

6 cinoma underwent endorectal MR imaging after cryosurgery.

7 en patients also underwent MR imaging before cryosurgery.

8 ; 2 patients also underwent open superficial cryosurgery.

9 ing siRNA specifically into the cytosol upon cryosurgery.

10 taneous Cryoablation, Intercostal Neuralgia, Cryosurgery, Ablation Techniques, Percutaneous, Thorax,

11 intralesional) alone or in combination with cryosurgery, allowing patients to continue therapy with

12 are crucial in applications such as rockets, cryosurgery and energy storage, where they can come in c

13 Long-term data are emerging to support cryosurgery, and large multicenter databases have been d

14 ed techniques, conventional scalpel surgery, cryosurgery, and photodynamic therapy) were included in

15 formal radiation therapy, brachytherapy, and cryosurgery), antiandrogen therapy management of erectil

16 00 times in not only the primary tumors with cryosurgery but also distant tumors without freezing.

17 All patients in the cryosurgery group responded, and seven of the eight cryo

18 Cryosurgery has a promising role in primary and salvage

19 ssful therapy and helped identify successful cryosurgery in patients who still had an elevated prosta

20 ential directions for future developments in cryosurgery include concepts to reduce side effects such

21 Cryosurgery-induced changes in the prostate gland preclu

22 frequentist network meta-analysis, including cryosurgery, ingenol mebutate, photodynamic therapy, col

23 Cryosurgery is a new method of treating prostate cancer.

24 ether shaving of the keloid scar followed by cryosurgery is associated with decreased scar volume.

25 gery group responded, and seven of the eight cryosurgery patients developed normal positron emission

26 Cryosurgery represents a transformative approach in the

27 , 5.95; 95% CI, 1.21-29.41; GRADE, low), and cryosurgery (RR, 4.67; 95% CI, 1.36-16.66; GRADE, very l

28 In the network meta-analysis, cryosurgery showed the highest participant complete clea

29 This is achieved by combining cryosurgery that causes "frostbite" of tumor with cold-r

30 The MTD for patients who did not undergo cryosurgery was 100 mg/m2 of irinotecan weekly for 3 wee

31 tial) among all patients who did not undergo cryosurgery was 74%.

32 cluding ALA-PDT, imiquimod, 5%, MAL-PDT, and cryosurgery was associated with significant long-term ef

33 cohorts of patients treated with or without cryosurgery were entered at escalating dose levels.

34 s) and cancer (2.4 +/- 1.0, 65 voxels) after cryosurgery were not statistically significantly differe